HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

Published online before print January 8, 2008

This Article Full Text Full Text (PDF) All Versions of this Article: jlb.1007675v1 83/4/1060    most recent Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Adalid-Peralta, L. Search for Related Content PubMed PubMed Citation Articles by Adalid-Peralta, L.

(Journal of Leukocyte Biology. 2008;83:1060-1067.)
© 2008 by Society for Leukocyte Biology

Stimulation of the primary anti-HIV antibody response by IFN- in patients with acute HIV-1 infection

Laura Adalid-Peralta^*,,1, Véronique Godot^*,,1, Céline Colin^,1, Roman Krzysiek^*,,, Thi Tran^*,, Pascal Poignard^||, Alain Venet^¶, Anne Hosmalin^**,, Pierre Lebon, Christine Rouzioux, Genevieve Chene, Dominique Emilie^*,,,2 the Interprim ANRS 112 Study Group³

^* INSERM U764, Clamart, France;
University Paris-Sud, Faculté de Médecine Paris-Sud, Institut Fédératif de Recherche, Clamart, France;
INSERM U593, University Victor Segalen Bordeaux 2, Institut de Santé Publique, d’Epidémiologie et de Développement, Bordeaux, France;
Assistance Publique-Hôpitaux de Paris, Hôpital Antoine Béclère, Service de Microbiologie-Immunologie Biologique, Clamart, France;
^|| Centre d’Immunologie de Marseille-Luminy, INSERM, Centre National de la Recherche Scientifique, University de la Méditerranée, France;
^¶ INSERM U822, Le Kremlin Bicêtre, France;
^** Institut Cochin, Département d’Immunologie, University Paris Descartes, Centre National de la Recherche Scientifique, Unité Mixte de Recherche 8104, Paris, France;
INSERM U567, Paris, France;
Assistance Publique-Hôpitaux de Paris, Hôpital Saint-Vincent de Paul, Service de Microbiologie, Paris, France; and
Laboratoire de Virologie, CHU Necker EA 3620, University Paris-Descartes, Paris, France

² Correspondence: INSERM U764, 32 rue des Carnets F-92140, Clamart, France. E-mail: dominique.emilie{at}u-psud.fr

ABSTRACT

Type I IFNs are needed for the production of antiviral antibodies in mice; whether they also stimulate primary antibody responses in vivo during human viral infections is unknown. This was assessed in patients acutely infected with HIV-1 and treated with IFN-2b. Patients with acute HIV-1 infection were randomized to receive antiretroviral therapy alone (Group A, n=60) or combined for 14 weeks with pegylated-IFN-2b (Group B, n=30). Emergence of anti-HIV antibodies was monitored during 32 weeks by Western blot (WB) analyses of serum samples. IFN-2b treatment stimulated the production of anti-HIV antibodies. On Week 32, 19 weeks after the last IFN-2b administration, there were 8.5 (6.5–10.0) HIV WB bands (median, interquartile range) in Group B and 7.0 (5.0–10.0) bands in Group A (P=0.054), and band intensities were stronger in Group B (P<0.05 for p18, p24, p34, p40, and p55 HIV antigens). IFN-2b treatment also increased circulating concentrations of the B cell-activating factor of the TNF family (P<0.001) and ex vivo production of IL-12 (P<0.05), reflecting its effect on innate immune cells. Withdrawal of antiretroviral treatment on Week 36 resulted in a lower rebound of HIV replication in Group B than in Group A (P<0.05). Therefore, type I IFNs stimulate the emerging anti-HIV immune response in patients with acute HIV-1 infection, resulting in an improved control of HIV replication. Type I IFNs are thus critical in the development of efficient antiviral immune responses in humans, including the production of antiviral antibodies.

Key Words: B lymphocyte • dendritic cell • B cell-activating factor • BAFF protein